Carregant...
Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes
The sodium‐glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduces heart failure in diabetes, but underlying mechanisms remain elusive. We hypothesized that empagliflozin could counteract the senescence of cardiac stromal cells (CSC), the action of which limits cardiac damage and cardiac fib...
Guardat en:
| Publicat a: | J Cell Mol Med |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7687009/ https://ncbi.nlm.nih.gov/pubmed/32940423 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.15699 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|